

# Epigenetics as a Modifiable Risk Factor in Periodontal Disease

Dr. Bhargavi R.<sup>1</sup>, Dr. Nagarathna D V<sup>2</sup>, Dr. Disha Rai<sup>3</sup>, Dr. Snehal Umesh<sup>4</sup>  
Post Graduate<sup>1,3,4</sup> PROFESSOR<sup>2</sup>

Department of Periodontics and Oral Implantology  
A J Institute of dental sciences, Mangalore, India-575004

**Abstract:-** Immunity and inflammation are governed through epigenetic mechanisms such as DNA and histone changes, which have arisen as imminent focuses for immune modulating drugs. The high commonness and grimness of periodontitis, as well as mounting proof that hereditary, natural, and way of life factors alone are insufficient to fully explain a person's susceptibility to disease development, has sparked interest in epigenetic regulation as a key factor in periodontitis pathogenesis. TLR2, PTGS2, IFNG, IL6, IL8, and TNF all have abnormal promoter methylation profiles in periodontitis patients' gingiva, blood, and buccal mucosa, which corresponds to changes in articulation and sickness seriousness. In periodontitis-impacted gingival tissue, the expression of histone deacetylases (HDACs), which regulate histone acetylation, is also dysregulated. Changes in chromatin-modifying enzyme expression and activity, as well as site-explicit and worldwide changes in DNA methylation designs, histone acetylation, and methylation marks, are all caused by *Porphyromonas gingivalis* or *Treponema denticola*. Epigenetic alterations are linked to inflammatory cytokines, chemokines, and matrix-degrading enzymes, and small molecule inhibitors of histone deacetylases (HDACi) or DNA methyltransferases can reduce their production. In animal models of periodontitis, HDACi and inhibitors of bromodomain-containing BET proteins reduce inflammation, osteoclastogenesis, and alveolar bone resorption, implying that they could be used as host modulation treatments in humans. To develop a full picture of epigenetic modifications in periodontitis, however, further epigenomic approaches would be required. Integrating functional research with a global epigenetic landscape analysis will reveal crucial information about epigenetics' restorative and symptomatic potential in periodontal disease.

## I. INTRODUCTION

Periodontitis is a fiery condition brought about by an oral microbial biofilm (dental plaque) that is expanding. While cornerstone microorganisms, for example, *Porphyromonas gingivalis*, *Tannerella forsythia*, and *Treponema denticola* assume a part in the foundation and movement of periodontitis, dysbiosis, not explicit periodontal microbes, is currently broadly recognized as the etiology of periodontitis [2]. Attacking insusceptible cells and native gingival cells, outstandingly gingival epithelial cells (GECs) and fibroblasts, discharge an overflow of cytokines, chemokines, and lattice debasing catalysts in a vain endeavor to free the gingival tissue of periodontal microbes. Persistent blend of these arbiters, then again,

advances incendiary tissue breakdown, which takes care of inflammophilic microorganisms. Accordingly, persistent irritation keeps a dysbiotic microbiota while likewise creating periodontitis-related tissue harm [3].

Constant periodontitis, which starts late and advances gradually, and forceful periodontitis, which starts early and advances quickly, are the two pathophysiologically particular illness types of non-necrotizing periodontitis [4]. While hereditary gamble factors are firmly connected to forceful periodontitis, the job of the hereditary part in ongoing infection patients is less clear [5]. Regardless of the new improvement of another periodontitis characterization framework [4], by far most of the epigenetic concentrates on examined in this audit were directed on quiet partners collected preceding the presentation of these grouping rules, and utilized the qualification among persistent and forceful infection. We'll go over research including people with the ongoing type of the infection, alluded to as periodontitis patients, as well as articles detailing forceful periodontitis patients, who advanced at a quicker than-normal rate.

Because of the great horribleness of periodontitis and related sicknesses, novel therapy methods are expected to enhance current bacterial test restricting methodologies (scaling and root arranging or root surface debridement). Therefore, have balance treatment, a momentous restorative technique, is acquiring prevalence. As indicated by this procedure, restorative medications that diminish the unfavorable impacts of the host's provocative reaction help conventional periodontal treatment [1]. The disclosure of significant jobs for epigenetic components in insusceptibility and irritation, as well as the mitigating capability of epigenetic drugs [6,7], moved this theory forward. This, along with proof that hereditary, natural, and way of life elements may not completely clear up an individual's powerlessness for sickness [8], has ignited interest in epigenetic guideline as a central participant in periodontitis pathogenesis and a likely objective for have tweak treatment.

## II. MECHANISMS OF EPIGENETIC INHERITANCE

The expression "epigenetics" has various definitions in logical writing [9]. This word will be utilized to allude to one of Bird's bringing together definitions: "chromosomal primary transformation to record, signal, or propagate fluctuating action levels," [10], with an emphasis on probably heritable adjustments that don't contain DNA succession changes [11]. DNA methylation and histone posttranslational adjustments are the most very much considered of these changes (PTMs).

The most predominant DNA change at CpG dinucleotides is cytosine methylation (cytosine followed by guanine). It for the most part brings about chromatin buildup and interruption of DNA-record factor collaborations, the two of which are connected to transcriptional suppression [12]. Stable oxidized 5mC subsidiaries, for example, 5-hydroxymethylcytosine (5hmC), are generally present all through genomic DNA in addition to 5-methylcytosine (5mC) residues. They're DNA demethylation intermediates [13] that play different roles in chromatin assembly [14]. DNA methylation marks are generated, recognised, and deleted at specified places. DNA methyltransferases (DNMTs) methylate cytosine residues, which can then be demethylated passively or actively (Fig 1a).In a compound

with UHRF1 (ubiquitin like with PHD and ring finger domains 1), DNMT1 is important for CpG methylation conservation after replication, but in a complex with DNMT3L, DNMT3a or DNMT3b catalyses de novo methylation [12]. TET (ten-eleven translocation) enzymes have the ability to oxidise 5mC and its oxidised derivatives in both passive and active demethylation. TDG and base-excision repair promote active demethylation by removing 5-formylcytosine (5fC) or 5-carboxylcytosine (5caC) from DNA (BER). When the DNMT1:UHRF1 complex fails to recognise the CpG site to be methylated as a result of 5mC oxidation, DNA undergoes passive demethylation during DNA replication [13].




Fig. 1

FIG 1: The atomic cycles of DNA methylation and histone acetylation are portrayed in this outline. DNMT3A or DNMT3B in blend with DNMT3L, the last option lacking methyltransferase action, can methylate unmethylated cytosine at the CpG site once more. After replication, the DNMT1:UHRF1 complex is vital for keeping up with the CpG methylation design on the reciprocal DNA strand. TET compounds catalyze the amalgamation of oxidized 5mC subsidiaries, which the DNMT1:UHRF1 complex does not perceive anymore (latent demethylation). TDG can likewise recognize and eliminate 5fC and 5caC, bringing about supplanting with unmodified cytosine through BER (dynamic demethylation). b HATs acetylate the N-terminal lysine deposits on histone tails, killing their positive charge, loosening up chromatin structure, and expanding transcriptional openness of quality advertisers. Bromodomain-containing proteins tie to specific acetyl-lysine-containing locales in histones, permitting acetylation-subordinate transcriptional buildings to frame. HDACs can deacetylate acetylated lysine buildups. UHRF1 Ubiquitin-like, having PHD and RING finger spaces 1, BER base-extraction fix, DNMT DNA methyltransferase, HAT histone acetyltransferase, HDAC histone deacetylase, TET ten-eleven movement, TDG thymine DNA glycosylase

To name a few PTMs, histones are acetylated, methylated, phosphorylated, citrullinated, and ubiquitylated. They affect transcriptional activity and chromatin structure in a variety of ways, many of which are context-dependent

[12]. It's proven challenging to employ histone PTMs as epigenetic markers because it's unknown if they're heritable. However, subsequent research has showed that a portion of these adjustments are mitotically tenacious in a locus-explicit way and that this legacy is physiologically critical [15, 16].

Acetylation is the most all around concentrated on histone PTM regarding administrative cycles and transcriptional results (Fig. 1b). Histone acetyltransferases (HATs) acetylate histone lysine buildups, while histone deacetylases (HDACs) deacetylate them [12]. Albeit different acetylation destinations assume assorted parts in this cycle, upgraded transcriptional action is altogether connected to histone acetylation. Acetylation of histone 3 lysine 56 [H3K56] and H4K16 causes chromatin construction to unwind by breaking electrostatic associations inside and between nucleosomes [17]. Wager proteins tie to acetylated lysines on H3 and H4 tails, which control record related exercises [18]. The connection among acetylation and deacetylation in transcriptional control is more muddled than recently suspected, as indicated by new exploration. Cap and HDAC action at dynamic and inert qualities was found to vary after genome-wide planning, recommending that unique acetylation and deacetylation cycles position latent qualities for future actuation [19]. In spite of its significance in transcriptional enactment, histone acetylation isn't adequate for quality articulation enlistment. Research on HDAC inhibitors backs this up (HDACi). Regardless of

the way that these synthetics cause worldwide histone hyperacetylation, they just impact a restricted level of deciphered qualities, with a large number of them being downregulated [20]. Histone methyltransferases (HMTs) lay out and histone demethylases eliminate lysine methylation, which influences chromatin design and quality articulation in a setting subordinate way [12]. For instance, transcriptional suppression has been associated with H3K27 and H3K9 trimethylation marks, while transcriptional actuation has been connected to H3K4Me3 and H3K36Me3 trimethylation marks [21].

Non-coding RNAs, especially microRNAs, are believed to be epigenetic components that oversee quality articulation by certain scientists. The job of non-coding RNA in periodontitis advancement, then again, has been researched [22, 23] and won't be talked about in this audit. Similarly, the significance of epigenetic guideline in periodontal infection has been generally explored with regards to bone digestion [24] and likely linkages with oncogenesis [25], subsequently we won't carefully describe the situation here. This survey will zero in on the impacts of epigenetic systems on sub-atomic and cell processes, as well as their clinical outcomes.

### III. PERIODONTITIS IS PORTRAYED BY POSTTRANSLATIONAL HISTONE ALTERATIONS AND CHROMATIN-CHANGING CHEMICALS.

#### A. *Changes in chromatin-altering chemical verbalization and limit*

Changes in the articulation and capacity of proteins that manage posttranslational histone alterations have been connected to an assortment of ongoing incendiary problems. To help endurance and break discovery by the safe framework, a few bacterial contaminations change histone acetylation in have cells [20]. It's not shocking those oral contaminations cause adjustments in the articulation examples of proteins engaged with chromatin redesigning in provocative gingival tissue and periodontal cells. The aftereffects of an overall HDAC articulation examination in periodontitis patients' and solid controls' gingival tissue were blended. Albeit the disparities were not approved at the protein level, Ateia et al. [26] found lower articulation of a few classes of chromatin-adjusting proteins, including class II HDACs, in periodontitis-impacted gingival tissue. Interestingly, an autonomous review found expanded record levels of a few HDAC relatives in periodontitis patients contrasted with sound people, including HDAC1, HDAC5, HDAC8, and HDAC9, however just HDAC1 articulation was affirmed at the protein level in immunohistochemical investigations of gingival tissue [27]. The clear inconsistencies between this exploration are hard to make sense of because of the little example sizes what's more, absence of careful clinical data on the patients examined. It's significant that expanded HDAC1 articulation in the gingiva has been connected to TNF-delivering cells [27]. Comparable positive connections among TNF and HDAC1, as well as other class I HDACs, have been accounted for in the synovial tissue of RA patients [28, 29], in spite of the distinctions not being checked at the protein level. Expanded degrees of HDAC1 in periodontitis might be because of the

persistent fiery cycle as opposed to communications with oral microbes, as per this revelation.

As per examinations of cells confined from periodontal tissues, oral contaminations alter HDAC articulation powerfully. Contamination with *P. gingivalis* decreased HDAC1 and HDAC2 articulation in GECs [30], yet contamination with *T. denticola* decreased record levels of various individuals from the class II HDAC family in periodontal tendon (PDL) cells, including HDAC4, HDAC6, and HDAC10 [26]. Oral diseases have been exhibited to increment worldwide H3K9 acetylation in GECs and gingival tissue in mice with periodontitis [31], and oral microorganisms and lipopolysaccharide (LPS) have been displayed to improve worldwide H3K9 acetylation in GECs and gingival tissue in people. Expanded H3K9 acetylation has been connected to HAT p300/CBP actuation [31], however HDAC articulation was not assessed in this examination.

The unique regulation of actuating and inhibitory histone methylation marks is expected for facilitated macrophage reactions to LPS [32]. Oral diseases, as per new examination, can cause fast changes in histone methylation in a few cell types. In PDL cells, LPS treatment delivers an abatement in abusive H3K27 trimethylation and an expansion in initiating H3K4Me3 marks on provocative quality advertisers [33, 34]. JMJD3 (KDM6B), a histone demethylase that catalyzes H3K27 demethylation, is enlisted to IL6 and IL12B advertisers and advances quality record [33]. In LPS-invigorated PDL cells, the H3K4 methyltransferase SETD1B is expanded and amasses on the advertisers of the IL6 and IL1B qualities [34]. These alterations trigger a transcriptional pathway that keeps PDL from going through osteogenic separation [35]. Extraordinary histone methylation fingerprints have been found in mice with trial periodontitis [36], which match disengaged cell populace information. Incendiary circumstances appear to manage the harsh H3K27Me3 mark the most powerfully. In periodontitis-impacted creatures, H3K27 trimethylation is expanded on the advertisers of qualities engaged with ECM turnover and diminished on the advertisers of cytokine, chemokine, and defensin qualities [36]. In any case, with regards to periodontal aggravation, changes in histone methylation marks on the advertisers of qualities managing early flagging occasions that are urgent for TLR-and cytokine-prompted reactions have not been explored.

#### B. *Bacterial metabolic items impact chromatin-changing proteins.*

Anaerobic microbes by implication influence HDAC work in periodontitis by their maturation items, which incorporate short-chain unsaturated fats (SCFAs), which have a HDAC inhibitory impact in certain circumstances. Millimolar levels of butyric and propionic acids are found in the gingival cleft of individuals with extreme periodontitis, which compare with incendiary and clinical markers of infection action [37,38]. Up to this point, analysts have just investigated the hurtful impacts of SCFAs created by oral microorganisms' HDACi action in the setting of viral contaminations. SCFAs created by *P. gingivalis* increment



lytic replication, reactivating inactive infections such Epstein-Barr infection [39,40] and Kaposi's Sarcoma-Associated Herpesvirus [41]. This is connected to expanded H4K12 acetylation, which increments viral chromatin transactivation [41], demonstrating that SCFA-intervened HDAC movement is huge in the clinical course of viral contamination. By downregulating histone methyltransferases EZH2 and SUV39H1, SCFAs have been exhibited to reduce confined histone trimethylation markers H3K27Me3 and H3K9Me3, showing that their consequences for have epigenetic systems go past HDAC restraint.

SCFAs created by oral microbes might affect gingival tissue structure cells, which could have an influence in periodontitis etiology. Butyric corrosive restrains as well as causes apoptosis in GEC and fibroblasts in vitro [42, 43]. Butyric corrosive increments bone resorption in osteoblasts through changing the RANKL/OPG proportion; nonetheless, this in vitro impact is incredibly subject to SCFA level and cell openness time [44]. SCFAs were found to safeguard against irritation intervened bone misfortune by lessening osteoclast separation without affecting bone arrangement in a new report [45]. To completely fathom the job of butyric corrosive and other bacterial metabolites in bone homeostasis in periodontitis, more examination is required.

*C. Little particle inhibitors of chromatin-altering catalysts stifle aggravation.*

Little particle inhibitors of chromatin-adjusting catalysts have been displayed to modify cell processes upset in infections like strange immunological enactment, connective tissue homeostasis interruption, and uncontrolled bone resorption [9, 46]. HDACi have acquired a great deal of interest in light of their calming and hostile to osteoclastogenic impacts [47]. In gingival fibroblasts treated

with the dish HDACi suberoylanilide hydroxamic corrosive (SAHA) and ITF2357 (givinostat), *P. gingivalis*-initiated articulation of a wide scope of provocative arbiters, including chemokines (CCL2, CCL5, and CXCL10), lattice metalloproteinases (MMP1, MMP3), and prostaglandin (PTGS2), is stifled [48]. HDACi forestall gingival fibroblast practicality and bacterial attack powerlessness in *F. nucleatum*-tainted or TNF-initiated cells [48]. HDAC3 hindrance is adequate for diminishing provocative qualities in gingival fibroblasts, as indicated by a board of HDACi with changed selectivity profiles [48]. Synovial fibroblasts [49] and macrophages [50] have approved these discoveries. In PDL cells invigorated by LPS, HDACi diminish TNF, IL-1, and responsive oxygen species creation, as well as *T. denticola*-intervened MMP2 initiation [26]. Synovial fibroblasts [49] and macrophages [50] have approved these discoveries. In PDL cells invigorated by LPS, HDACi diminish TNF, IL-1, and responsive oxygen species creation, as well as *T. denticola*-interceded MMP2 enactment [26].

HDACi restrains incendiary initiation in PDL cells while expanding osteoblast markers, RUNX2 levels, soluble phosphatase action, and mineralized knob arrangement, which are all signs of osteogenic separation [51, 52], proposing that these mixtures could help alveolar bone recovery. HDAC3 articulation was viewed as fundamentally downregulated during PDL cell separation into osteoblasts, which was helped by HDACi [52]. These information show that restraining HDAC action, especially HDAC3, might be helpful in bringing down irritation and supporting tissue recovery in people with periodontitis (Table 1). HDACs may subsequently be a suitable choice for have alteration treatment.

Epigenetic target	Compound(s)	Effect
HDACs	SAHA, ITF2357	Suppression of <i>P. gingivalis</i> - and cytokine-induced CCL2, CCL5, CXCL10, MMP1, MMP3 and PTGS expression in gingival fibroblasts [53]
	TSA, butyrate	Upregulation of hBD2, IL-8 and CCL20 in GECs infected with <i>P. gingivalis</i> or <i>F. nucleatum</i> [35]
	butyrate	Suppression of LPS-induced TNF and IL-1 $\beta$ expression and ROS production in PDL cells [56]
	TSA, apicidin	Suppression of <i>T. denticola</i> -induced MMP2 activation in PDL cells [29]
	TSA, butyrate	Upregulation of osteoblast markers and induction of osteogenic differentiation of PDL cells [56, 57]
	1179.4b	Reduction of alveolar bone destruction in experimental periodontitis in mice [69]
	TSA	Reduction of inflammation and increased alveolar bone volume in experimental periodontitis in rats [68]
BET proteins	I-BET151, JQ1	Suppression of inflammatory mediator production by GECs and gingival fibroblasts [65]
	JQ1	Amelioration of inflammation and alveolar bone resorption in experimental periodontitis in mice [70]
DNMTs	AZA	Induction of differentiation of gingival fibroblasts into osteoblasts and induction of ectopic bone formation in mice [120]
		Suppression of <i>T. denticola</i> -induced MMP2 activation in PDL cells [29]
	AZA, decitabine	Modulation of inflammatory cytokine production by GECs [121]
	RG108	Prevention of <i>P. gingivalis</i> -mediated impairment of GEC barrier function [114]

Table 1: shows the impacts of little atom epigenetic controller inhibitors in cell and creature periodontitis models

Regardless of the shortfall of exhaustive investigations on the impacts of HDACi on GEC initiation, primer proof recommends that these mixtures might expand IL8, CCL20, and hBD2 articulation in GECs contaminated with *P.*

*gingivalis* or *F. nucleatum* [30]. HDACi have been proposed to help natural safe reactions against oral diseases by initiating human-defensin-2 (hBD2) and CCL20 because of their antibacterial properties. This isn't shocking considering

the revelation of antimicrobial peptides in epithelial cells from a few organs [53]. Notwithstanding, some *P. gingivalis* strains are impervious to hBD2 bactericidal activity [54], and CCL20's immediate antibacterial viability against oral contaminations still can't seem to be laid out. These discoveries show how HDAC action controls insusceptible reactions at the cell level, however further exploration is expected to totally comprehend what HDAC inhibitors mean for the by and large incendiary go between result of periodontal tissues. Human gingival tissue explant tests, then again, are troublesome because of a deficiency of material. Accordingly, newly built organotypic 3D models comprised of GECs and gingival fibroblasts [55], which in numerous perspectives intently mirror certifiable gingiva, might be significant for this reason.

Albeit most of exploration has zeroed in on repressing HDAC action in gingival cells, a couple of new investigations have investigated different pieces of chromatin-based epigenetic systems that can be focused on with minuscule pharmacologic inhibitors. The revelation of acetylated histone mimetics that block bromodomain-containing BET proteins from communicating with histone proteins with acetylated lysine buildups has opened up another line of investigation into the meaning of protein acetylation in human issues [56]. In myeloid cells [57], synovial fibroblasts [58], and in vivo models of incendiary illnesses [58,59], these synthetic compounds have been demonstrated to be especially successful in diminishing irritation. A new report [60] exhibited that the BET inhibitors I-BET151 and JQ1 diminish fiery quality articulation in gingival fibroblasts and the GEC line TIGK (telomerase-deified gingival keratinocyte). Wager inhibitors decrease the development of incendiary middle people in GFs from solid benefactors and periodontitis patients [60]. They additionally stop *P. gingivalis* from initiating gingival cells and creating incendiary cytokines. I-BET151 and JQ1 block arbiters such IL-6, IL-1, and CCL2 in gingival fibroblasts and GECs, and more prominent levels of these go between are most regularly recognized in periodontitis patients [61]. This demonstrates the way that BET inhibitors can decrease periodontal aggravation's key arbiters.

The helpful viability of medications that control histone methylation, especially the H3K4Me3 and H3K27Me3 marks, has been explored in cell and creature models of periodontitis [36], however the restorative adequacy of drugs that regulate this cycle still can't seem to be checked. Control of proteins that oversee histone methylation can diminish provocative initiation and influence the capacity of PDL cells to form into osteoblasts, as per quality quieting study. JMJD3 quieting brings down LPS-initiated IL-6, IL-8, and IL-12 creation as well as basic phosphatase movement, suggesting a lower osteogenic potential [33, 35]. Lower H3K4Me3 levels at the IL6 and IL1B advertisers are connected with diminished IL6 and IL1B articulation when SETD1B is taken out [34]. More review is expected to check whether pharmacological balance of histone methylation controllers can duplicate the impacts of quality hushing and decrease periodontitis-related provocative cycles. GSK-J1, a JMJD3 inhibitor, has been

displayed to have serious areas of strength for a provocative effect in macrophages [67].

#### *D. Histone PTMs are the focal point of in a periodontitis model.*

In rodents with exploratory periodontitis, focusing on histone acetylation with HDACi or acetylated histone mimetics safeguards against alveolar bone misfortune in vivo [62,63,64]. (As delineated in Table 1) The helpful benefits of HDACi in mice with periodontitis brought about by *P. gingivalis* depend on their selectivity: MS-275 (which exclusively targets HDAC1) was demonstrated to be less viable in forestalling bone debasement than 1179.4b (which targets both class I and class II HDACs) [63]. Shockingly, bone misfortune security in HDACi-treated mice was not connected to a decrease in invulnerable cell invasion [63]. These discoveries propose that the impact of HDACi on sickness seriousness was inconsequential to aggravation, in some measure in this creature. 1179.4b's defensive impact could be connected with HDACi's effect on alveolar bone recovery, provided their legitimate ability to diminish osteoclastogenesis [65] and gathering proof that these medications advance osteogenic separation of PDL cells [51, 52]. The capability of HDACi to advance osteogenic separation of mesenchymal undifferentiated cells was connected to TSA's bone-defensive impacts in ligature-incited periodontitis in rodents [62], yet this impact has not been completely confirmed in vivo.

In a mouse periodontitis model, HDACi significantly affected irritation [63], which must be affirmed autonomously utilizing HDACi with very much portrayed pharmacokinetic properties and an attention on immunological and microbiological sickness markers. In mice with trial periodontitis, the BET inhibitor JQ1 decreased both alveolar bone resorption and incendiary cytokine levels [64]. JQ1's defensive impacts were connected to diminished osteoclast creation [64], which is predictable with discoveries in other bone-related sicknesses [66]. As a result of their capacities in bone resorption, HDACs and BET proteins seem, by all accounts, to be likely focuses for have regulation treatment. HDAC inhibitors [67] and BET inhibitors [68] have been displayed to make mice more vulnerable to bacterial contaminations. Thus, concentrating on the impacts of these medications on plaque arrangement and bacterial leeway in periodontitis creature models will be pivotal.

## **IV. METHYLATION OF DNA IN PERIODONTITIS**

### *A. Clinical discoveries: strange DNA methylation in periodontitis patients' examples*

A few examinations have taken a gander at the DNA methylation profiles of different quality advertisers in hereditary material gathered from human gingival biopsies. The advertiser methylation status of qualities coding for proteins ensnared in provocative tissue reactions, as well as receptors, flagging atoms, and record factors, was found in periodontitis patients. The distinctions in advertiser methylation between patients with periodontitis and sound individuals were not recreated in that frame of mind in a few investigations [69]. It's likewise important the

inconsistencies between studies, for example, contrasts in advertiser methylation between periodontitis patients and solid individuals saw in certain examinations for IFNG, IL6, IL8, TNF, and TLR2. Just the discoveries of PTGS2 [70] and STAT5A [71], which showed expanded and diminished methylation in periodontitis patients, were reliable across many examinations. Notwithstanding the absence of explicit

qualities or quality bunches, a high-throughput microarray assessment of DNA methylation in solid benefactors and patients with periodontitis tracked down more variety in changes in resistant related qualities, as well as additional incessant decreases in their advertiser methylation [72].

Gene promoter	Study authors	Number of participants (healthy individuals: patients with periodontitis)	Outcome
<b>Genes associated with tissue responses</b>			
IFNG	Zhang et al. [75]	23:12 (+ 12 participants with experimentally induced gingivitis)	↓ (no difference between experimentally induced gingivitis and healthy subjects)
	Viana et al. [76]	16:18	—
	Asa'ad et al. [77]	10:10 (methylation was also assessed 2 and 8 weeks post-therapy)	— (no change in the course of periodontal therapy)
IL6	Barros and Offenbacher [78]	10:10	↑
	Kobayashi et al. [79]	30:30	—
IL10	Stefani et al. [80]	21:21	—
	Viana et al. [76]	16:18	—
IL17	Barros and Offenbacher [78]	10:10	↑
IL17C	Schulz et al. [89]	10:15 (aggressive periodontitis patients)	↓
CXCL3	Barros and Offenbacher [78]	10:10	↑
	Schulz et al. [89]	10:15 (aggressive periodontitis patients)	—
CXCL5	Barros and Offenbacher [78]	10:10	↑
	Schulz et al. [89]	10:15 (aggressive periodontitis patients)	—
IL8	Barros and Offenbacher [78]	10:10	↓
	Oliveira et al. [81]	41:70 (periodontitis group divided into 30 smokers and 40 non-smokers)	— (no difference between smokers and non-smokers)
CXCL10	Barros and Offenbacher [78]	10:10	↑
CCL25	Schulz et al. [89]	10:15 (aggressive periodontitis patients)	↓
TNF	Zhang et al. [82]	17:18 (+ 11 participants with experimentally induced gingivitis)	↑ (no difference between experimentally induced gingivitis and healthy subjects)
	Asa'ad et al. [77]	10:10 (methylation was also assessed 2- and 8-weeks after therapy)	— (no change in the course of periodontal therapy)
PTGS2 (COX2)	Zhang et al. [84]	6:10	↑
	Loo et al. [85]	108:110 (comparison between blood samples from healthy donors and gingival tissue biopsies from patients with periodontitis)	↑
	Asa'ad et al. [77];	10:10 (methylation was also assessed 2- and 8-weeks after therapy)	↑ (periodontal treatment reduced the methylation status to the levels observed in healthy subjects)
<b>Genes coding for receptors, signaling molecules and transcription factors of inflammation-related pathways</b>			
TLR2	de Faria Amorimino et al. [86]	20:20	↑
	De Oliveira et al. [83];	11:23 (periodontitis group was divided into 11 smokers and 12 non-smokers)	— (inconclusive results: mosaic of methylated and unmethylated DNA. Site-specific (restriction enzyme-specific) trend toward increased methylation in periodontitis non-smokers)
	Barros and Offenbacher [78]	10:10	— (strong trend toward decreased methylation in patients with periodontitis, which did not reach statistical significance)
TLR4	De Oliveira et al. [83];	11:23 (periodontitis group was divided into 11 smokers and 12 non-smokers)	— (no difference between smokers and non-smokers)
	Barros and Offenbacher [78]	10:10	↓
IL4R	Schulz et al. [89]	10:15 (aggressive periodontitis patients)	—
	Barros and Offenbacher [78]	10:10	↑
IL6ST	Schulz et al. [89]	10:15 (aggressive periodontitis patients)	—
	Barros and Offenbacher [78]	10:10	↑
TNFRSF18	Barros and Offenbacher [78]	10:10	↓
STAT5A	Barros and Offenbacher [78]	10:10	↓
	Azevedo et al. [87]	20:20	—
TYK2	Barros and Offenbacher [78]	10:10	—
	Schulz et al. [89]	10:15 (aggressive periodontitis patients)	—
SOCS1	Planillo et al. [146]	44:46	↓

Table 2: Changes in advertiser methylation of chosen qualities in periodontitis patients' gingival tissue

Changes in DNA methylation designs in periodontitis are not restricted to the area of irritation. Changes in the methylation status of quality advertisers have likewise been distinguished in blood tests (Table 3). In the fringe blood of people with periodontitis, expanded methylation of the TNF advertiser region [74] and diminished methylation of the IL6 advertiser locale [75] have been found, though the last

disclosure has not been confirmed in an ensuing exploration. The methylation of the IL6 advertiser in the blood is fundamentally higher than in gingival tissue, and worldwide 5hmC levels in tissue and blood are comparable [76]. CXCL1, IL1B, IL6ST, and CD44 have all been viewed as methylated differentially in those experiencing periodontitis [77].



Gene promoter	Study authors	Number of participants (healthy individuals:patients with periodontitis)	Outcome
<b>Blood</b>			
TNF	Kojima et al. [90]	30:30 (+30 patients with RA)	↑ (the same effect observed in RA, but in higher number of CpG sites)
	Kobayashi et al. [79]	30:30	—
IL6	Ishida et al. [91]	30:30 (+30 patients with RA)	↓ (the same effect observed in RA)
	Kobayashi et al. [79]	30:30	—
VDR	Kurushima et al. [93]	EWAS twin study, correlation with 2 different periodontal traits was analyzed separately in participants from TwinsUK registry (83% monozygotic and 10% dizygotic twins)	↓
IL6ST			
TMCO6			
IL1RN			
CD44			
IL1B			
WHAMM			
CXCL1			
<b>Buccal mucosa</b>			
IL8	Oliveira et al. [81]	41:70 (periodontitis group was divided into 30 smokers and 40 non-smokers)	↓ (no difference between smokers and non-smokers)
	Andia et al. [94]	37:37 (aggressive periodontitis patients)	↓
SOCS1	Baptista et al. [95]	30:30 (aggressive periodontitis patients)	↑
VDR	Kurushima et al. [93]	EWAS twin study, correlation with 2 Different periodontal traits were analyzed separately: Gingival bleeding (43 participants: 18 negative vs 25 positive; 20 monozygotic twins, 16 dizygotic twins and 7 singletons)	↓
IL6ST			
TMCO6			
IL1RN			
CD44			
IL1B			
WHAMM			
CXCL1			
MMP13			
MED24			
CCR1			
MMP3			
TLR4			
IL6			
IL10			
SNORD124			

The numbers of participants in both groups (healthy individuals: patients with periodontitis) are shown in parentheses for each study. ↓—decreased methylation in patients with periodontitis compared to healthy controls; ↑—increased methylation in patients with periodontitis compared with healthy controls; —no difference between groups; ↓—differential methylation (effect direction not stated)

Table 3: Changes in advertiser methylation of chosen qualities in periodontitis patients' blood and buccal mucosa

In the buccal mucosa of periodontitis patients, changes in site-explicit DNA methylation have additionally been found. Buccal epithelial cells from periodontitis patients had lower methylation levels of the IL8 advertiser area than sound controls, in spite of no irregularities in gingival biopsies. In buccal epithelial cells from people with forceful periodontitis, methylation levels of the IL8 advertiser were viewed as lower [78], yet methylation levels of the SOCS1 advertiser and the long-scattered nucleotide components (LINE1 components) were viewed as higher [79]. LINE1 components are DNA areas that are known to be intensely methylated. Thus, they're often utilized as a substitute for overall DNA methylation [80]. The EWAS investigation [77] found a comparable profile of connections between DNA methylation and periodontal qualities for few qualities across blood and buccal tissue. Understanding epigenetic changes in the buccal mucosa could be significant for finding in light of the fact that the microbiota of the buccal mucosa is modified in people with periodontal sickness [81] and the tissue is effectively open.

The outflow of DNA methyltransferases and demethylating proteins, as well as worldwide DNA methylation levels, were estimated in gingival tissues notwithstanding quality explicit methylation studies. In gingival biopsies from periodontitis patients and solid controls, record levels of DNMT1 and DNMT3a are

comparative [82]. Larsson et al. found no varieties in DNMT1 articulation between patients with periodontitis and gum disease. Besides, immunohistochemistry uncovered no distinctions in worldwide 5mC or 5hmC levels. TET2-positive cells were found in more noteworthy numbers in periodontitis patient examples [76], however they were not connected to changes in TET2 mRNA articulation altogether gingival tissue, proposing that the effect could be ascribed to the example's cell heterogeneity. Generally, these discoveries uncover that varieties in advertiser explicit methylation profiles saw in periodontitis aren't driven by worldwide DNA hypermethylation or changes in the outflow of catalysts that direct this cycle altogether gingival tissue tests. All things considered, they are probably going to be initiated locally by bacterial mixtures or the fiery milieu, and they are cell type explicit.

Investigations of the association between DNA methylation and quality articulation have laid out the natural meaning of the revealed changes in DNA methylation in periodontitis. TNF, PTGS2, TLR2, and IFNG [69] were accounted for to have negative connections between DNA methylation at quality advertiser areas and quality articulation in gingival biopsies, however IL8 had a positive relationship in oral epithelial cells. TNF [74], yet not IL6 [75], advertiser methylation associates adversely with serum protein levels in blood tests. A high-throughput examination

found a negative association between DNA methylation levels inside quality advertisers and quality articulation in gingival tissue [72]. Notwithstanding their significance, they are deficient for recognizing explicit quality organizations and early flagging occasions that are dysregulated in excited gingival tissue by means of epigenetic pathways and may address helpful targets. Hardly any qualities coding for receptors, flagging particles, and record factors have been concentrated in little quiet companions (Table 2). To find upstream flagging pathway parts that are dysregulated in periodontitis because of modifications in DNA methylation, very much planned high-throughput epigenomic and transcriptome tests are required (or other epigenetic systems).

Two unique examinations searched for plausible connections between periodontitis patients' clinical analytic measures and DNA methylation of specific quality advertisers, and recognized relationships for two advertiser locales (positive relationship for TLR2 and negative for IL-6). Quality methylation status, then again, was found to have no connection to clinical connection misfortune (CAL) or the level of draining examining locales (BOP). As indicated by De Faria Amormino et al. [83], methylation of the TLR2 advertiser was associated with the quantity of provocative cells in periodontal tissue from both sound givers and periodontitis patients. Contrasts in the phone creation of sound and aggravated tissue, outstandingly the convergence of leukocytes during irritation, could make sense of part of this association [83]. A deluge of a particular lymphocyte populace might actually make sense of changes in GATA3 methylation found in periodontitis [71]. In periodontitis-impacted gingival tissue, expanded quantities of provocative cells are connected to spatial varieties in quality articulation [84]. A comparative geographic investigation of DNA methylation in mix with quality articulation profiling could fundamentally support a superior comprehension of the impacts found in entire tissue test research. Contrasts in the phone structure of solid and excited tissue, outstandingly the deluge of leukocytes during aggravation, could make sense of part of this association [83]. A flood of a particular lymphocyte populace might actually make sense of changes in GATA3 methylation found in periodontitis [71]. In periodontitis-impacted gingival tissue, expanded quantities of fiery cells are connected to spatial varieties in quality articulation [84]. A comparable geographic investigation of DNA methylation in blend with quality articulation profiling could altogether support a superior comprehension of the impacts found in entire tissue test research.

During incendiary reactions, record factor restricting causes demethylation of specific CpG destinations, coming about in a heterogenic methylation design inside specific advertisers [85, 86]. The utilization of different methylation-touchy proteins uncovered that DNA methylation inside the TLR2 advertiser in gingival tissue is heterogeneous. A pattern toward higher methylation in periodontitis patients was distinguished in a similar report for a solitary CpG area, yet not for the whole TLR2 advertiser. Pyrosequencing of the TNF and IFNG [69] qualities exhibited comparative methylation variety inside individual advertisers and site-

explicit changes in solid benefactors and periodontitis patients. Notwithstanding, using strategies that exclusively recognize site-explicit DNA methylation, for example, bisulfite-transformation or processing based PCR techniques, a portion of the distinctions in advertiser methylation results between studies could be made sense of [87]. The noticed inconsistencies could be made sense of by contrasts in tolerant incorporation measures, as well as specialized factors in example assortment and handling.

At last, nothing is known with respect to the effect of likely bewildering factors on periodontitis patients' accounted for changes in DNA methylation. Cell heterogeneity in tissue biopsies (as well as entire blood tests) might be the most significant confounder in cross-sectional examination [88]. Varieties in DNA methylation across the gingival tissue may not address contrasts in unambiguous cell types, it's important. Utilizing the laser catch microdissection approach, Barros et al. [71] gathered GECs from gingival tissue biopsies and found a bunch of fiery qualities with expanded methylation levels in cells from periodontitis patients (TYK2, IL17C, IL12B, CCL25, CXCL14, IL4R). Just CXCL14 showed a comparative impact in periodontitis-impacted gingival tissue from similar people when contrasted with qualities with changed methylation profiles [71]. Periodontitis vulnerability factors like hereditary variety, age, and natural gamble variables might affect DNA methylation freely of infection related pathways [88]. Smoking is a huge, preventable gamble factor for periodontal infection [89], and it straightforwardly affects DNA methylation [90]. In two examinations, advertiser explicit modifications in DNA methylation in smokers and non-smokers with periodontitis were inspected, with practically no distinctions recognized (Table 2). As individuals age, changes in DNA methylation are connected to higher mortality in an assortment old enough related diseases, as well as actuation of supportive of incendiary pathways [91]. Stoutness and liquor admission [92], which are both rising periodontitis risk factors [93] however presently can't seem to be inspected, affect these modifications.

#### *B. Changes in DNA methylation designs in periodontal inhabitant cells*

Oral contaminations and provocative improvements seem to produce quality explicit hypermethylation in gingival cells, as per investigations of DNA methylation at explicit quality advertisers. As per Benakanakere et al. [94], the most over the top total work to date, diminished provocative reactions to *P. gingivalis* in GECs from a subset of periodontitis patients are connected to bring down TLR2 articulation and expanded methylation of the TLR2 advertiser locale. Persistent disease with *P. gingivalis* causes hypermethylation of the TLR2 advertiser in both GEC cells and murine gingiva [94]. TLR2 is a critical controller of safe reactions to *P. gingivalis* and is expected for the improvement of neurotic aggravation in periodontitis models in mice [95], recommending that DNA methylation might assume a part in directing GEC reactions to this periopathogen (Fig. 2).






Fig. 2

Expanded methylation and decreased articulation of qualities coding for parts of the cell intersection edifices (CDH1, PKP2, and TJP1) are brought about by *P. gingivalis* disease of GECs, bringing about practical breakdown of the epithelial hindrance [96]. After delayed excitement with *P. gingivalis* LPS, different qualities encoding ECM parts, including FANK1, COL4A1-A2, COL12A1, COL15A1, LAMA5, LAMB1, MMP25, POMT1, and EMILIN3, are hypermethylated in PDL cells, which is connected to bring down articulation levels of these qualities.

DNMT articulation as well as worldwide changes in DNA methylation in light of specific factors embroiled in periodontitis movement have been concentrated in an assortment of studies utilizing confined gingival and periodontal cell populaces. After disease with *P. gingivalis* or *F. nucleatum*, essential GECs showed a decrease in DNMT1 articulation [30]. In PDL immature microorganisms and the HaCat keratinocyte cell line, treatment with *P. gingivalis* LPS causes DNMT1 downregulation, however not in gingival fibroblasts [82]. In HaCat cells presented to *P. gingivalis* LPS, DNMT3a mRNA articulation is in like manner diminished [82]. PGE2 downregulates both DNMT1 and DNMT3a articulation, while IL-1 upregulates DNMT1 and downregulates DNMT3a articulation in gingival fibroblasts. After excitement with either IL-1 or PGE2, gingival fibroblasts showed more prominent worldwide 5mC levels in spite of downregulation of both DNMTs, with the last option having a more grounded impact notwithstanding downregulation of both DNMTs.

Decitabine and 5-aza-2'-deoxycytidine (AZA) are cytotidine primary analogs that can be used to restrain

DNMT1 and different targets. Expanded articulation of osteogenic genealogy markers RUNX and ALP is associated with demethylation of their advertiser locales in gingival fibroblasts treated with AZA. Besides, pretreatment with AZA before culture within the sight of BMP2 leads gingival fibroblasts to form into utilitarian osteoblasts, suggesting that this could be a potential bone recovery helpful technique. *T. denticola*-actuated overexpression of MMP2 and parts of its enacting complex (MT1-MMP and TIMP-2) is additionally stifled in PDL cells by DNMT1 restraint with AZA, yet it is hazy assuming this is connected with changes in MMP2 advertiser methylation status. Pretreatment with AZA expanded the outflow of CCL20, hBD2 [30], and IL-1 created by *P. gingivalis* while diminishing the acceptance of IL-6 and CXCL1 by *P. gingivalis* or *F. nucleatum*. Prior to contamination with *P. gingivalis*, decitabine-treated GECs showed a comparative example of quality articulation adjustments, however not with *F. nucleatum*. Nonetheless, GECs were simply presented to DNMT1 inhibitors for a short time frame (4 h) before disease in these examinations, which may not be sufficient to prompt DNA hypomethylation. At last, pretreatment of GECs with non-nucleoside DNMT inhibitors (RG-108, EGCG, or curcumin) turned around the impacts of *P. gingivalis* on methylation and articulation of a bunch of qualities encoding cell intersection complex parts, as well as the utilitarian disturbance of the gingival epithelial obstruction [96].

TET catalysts, which are associated with DNA demethylation, are associated with gingival cell enactment. In gingival fibroblasts, feeling with IL-1 or PGE2 incites diminished TET1 quality record yet expanded 5hmC levels. TET1 has more enzymatic action toward 5mC than its oxidized subsidiaries, in this manner its decreased

articulation may not be sufficient to additionally oxidize 5hmC, bringing about DNA change aggregation. Notwithstanding, it ought to be accentuated that feeling prompted expansions in 5hmC levels in gingival fibroblasts are joined by simultaneous decreases in 5mC levels. It's obscure what supportive of fiery excitement means for the combination of other TET proteins in these cells, especially TET2, which is associated with natural invulnerable reactions in myeloid cells [16]. TET compounds have been shown to shield specific CpG locales from methylation, hence downregulation of TET1 in gingival fibroblasts in light of fiery feeling ought to assist with making sense of a portion of the DNA hypermethylation seen notwithstanding lower DNMT1 and DNMT3a articulation. After co-feeling with *P. gingivalis* LPS and IFN-, TET1 is engaged with the separation of THP-1 cells into M1 macrophages [98]. After LPS feeling, TET2 knockdown diminishes cytokine creation in dental mash cells, which is connected to diminished MYD88 quality advertiser hydroxymethylation and NF-B flagging [99]. Since these discoveries are predicated on quality quieting, it's memorable's critical that TET chemicals could adjust insusceptible reactions by systems other than DNA demethylation, for example, HDAC2 enrollment [100]. Moreover, examinations in dendritic cells infer that DNA demethylation is an outcome as opposed to a reason for expanded quality articulation [86].

#### C. DNA methylation studies in periodontitis in vivo

Creature models of periodontitis are a helpful instrument for evaluating the spatiotemporal variations found in understanding inferred materials, however they are seldom utilized to survey DNA methylation. DNMT3b immunohistochemistry was as of late utilized as a marker of once more DNA methylation in mouse periodontitis models to examine the connection among nearby and fundamental contamination [101]. Palioto et al. [101] saw that foundational oral gavage microbial test with *P. gingivalis* builds DNMT3b levels in gingival tissue, especially on the alveolar bone surface, however not neighborhood ligature challenge. Comparative adjustments in DNMT3b articulation have been seen in the stomach epithelium, proposing that epigenetic instruments might be associated with the foundational impacts of the bacterial attack [86]. In vitro discoveries, for example, upgraded TLR2 advertiser methylation in the gingival tissue of mice treated with *P. gingivalis* [94] and the improvement of ectopic bone development by the DNMT inhibitor AZA have been approved or enhanced utilizing mouse models.

Gingivitis can be utilised to study the early stages of periodontitis in people [102], which is caused by not brushing or flossing your teeth. The expression of IFNG mRNA was higher in this model than in patients with periodontitis, but it recovered to normal once the inflammation was resolved [69]. Surprisingly, unlike in periodontitis patients, this increase in gene expression was not accompanied by a decrease in IFNG promoter methylation in fake gingivitis patients. TNF promoter methylation was similarly higher in periodontitis patients but not in experimental gingivitis, and periodontitis patients had lower mRNA levels. Because gingivitis, unlike periodontitis, is a reversible form of inflammation, these

findings may suggest that changes in DNA methylation have a role in the failure of inflammation resolution, which is a crucial component of periodontal aetiology. For example, periodontal therapy can rectify pathogenic alterations in DNA methylation. The methylation status of the PTGS2 advertiser, which was contrastingly methylated in people with periodontitis contrasted with sound individuals, was reestablished to levels related with periodontal wellbeing after customary periodontal treatment, as per Asa'ad et al. [70].

#### D. Epigenetic changes in periodontitis could be employed as a diagnostic and therapeutic target.

Explicit DNA methylation marks in blood tests have been examined widely as biomarkers of particular kinds of disease as of late, and clinical measures for recognizing them have now opened up [103], making ready for the utilization of DNA methylation in the diagnostics of issues with hidden epigenetic systems [104]. Differential DNA methylation has been connected to irritation and is being concentrated as a potential biomarker in an assortment of sicknesses, including Crohn's illness [105], lupus [106], and RA drug reaction [107]. Both advertiser explicit investigations [74] and EWAS [77] have found changed DNA methylation marks in blood tests from periodontitis patients (Table 3), raising the possibility that some of them could be utilized for analytic reasons after approval in bigger patient partners. Their linkages to sickness helplessness, movement, or seriousness, then again, still can't seem to be shown, which will be expected before they can be named infection biomarkers. Buccal epithelial cells from individuals with persistent and forceful [78,79] types of the sickness showed changed DNA methylation designs, making it one more effectively open tissue for demonstrative purposes. Since buccal tissue collaborates more intimately with pathogenic oral greenery than fringe blood tests, it might give more significant data about infection movement [81].

To determine their applicability, it will be necessary to identify confounding factors that may affect the applicability of potential epigenetic markers in diagnostic tests, as well as sufficient control group selection. At different CpG sites and around the world, DNA methylation patterns differed between gingival biopsies, buccal mucosa, and blood samples [76]. It's unclear if the variations are due to changes in cellular sample makeup, a well-known confounder in epigenetic investigations [88], or variances in disease pathobiology. Other known influences on DNA methylation designs, for example, hereditary polymorphisms, age [88], and natural gamble factors [108], should likewise be thought of.

The outcome of epigenetic drugs in oncology, as well as the disclosure of calming qualities in HDAC and BET inhibitors, have stressed the guarantee for focusing on epigenetic changes for the treatment of a wide scope of sicknesses. The primer clinical adequacy of HDACi in patients with join versus-have sickness [109] and foundational beginning adolescent idiopathic joint pain [110], as well as an acceptable profile of side effects seen in these trials, has sparked interest in using HDACi to treat

immune-mediated inflammatory diseases. Targeting HDACs or BET proteins in periodontitis may be advantageous by lowering excessive inflammation and restoring bone homeostasis, according to available *in vitro* and *in vivo* evidence.

Endeavors to target epigenetic anomalies in periodontal disease patients, on the other hand, should be approached with caution. Broad-spectrum HDACi cause thrombocytopenia, neutropenia, tiredness, and diarrhoea, among other dose-limiting side effects, according to evidence from clinical study in cancer patients. Patients with life-threatening cancers may be able to withstand such a list of nasty side effects, but those with less serious illnesses will not. HDACi, on the other hand, exhibit anti-inflammatory activities at much lower concentrations than those required to trigger tumour cell death. As a result, the doses needed to achieve efficacy in people with inflammatory illnesses will almost certainly be safer. Similarly, selective HDAC inhibitors that target specific HDACs are less likely to cause harm while still having anti-inflammatory effects comparable to pan-HDAC inhibitors. HDAC3 inhibition appears to be adequate to diminish inflammatory activation *in vitro* [48], despite the fact that HDAC3-selective medications have yet to reach clinical trials. Second, while the main purpose of host modulation therapy is to reduce chronic, non-resolving inflammation, it should not impair the host's ability to respond to oral and other infections [1]. While HDACi-mediated antimicrobial peptide production by epithelial cells may improve pathogen clearance, stifling macrophage and dendritic cell safe reactions might expand vulnerability to specific bacterial or contagious contaminations, according to the existing findings [111]. Concerns about BET inhibitor use in periodontitis should be addressed as well. These drugs have advanced to cancer clinical trials [141], but their effects on host-pathogen interactions have yet to be determined in patients with inflammatory disorders.

To decide the likely outcomes of epigenetic treatments on oral wellbeing and to decide the best method of medication organization, complete *in vivo* investigations analyzing the drawn-out impacts of HDACi or BET inhibitor treatment on have reactions to dysbiotic oral microflora (as well as different microorganisms not connected with the oral microbiota) are required. In the writing, there is no definitive proof that epigenetic changes ought to be dealt with foundationally or locally at the site of irritation. The relative commitments of dysregulated epigenetic cycles to the pathogenic initiation of assorted cell types that cause tenacious aggravation in periodontitis will choose this. These cell type-explicit impacts might be difficult to address in human investigations of cutting-edge sickness, requiring the utilization of a very much planned creature model and long-haul periodontitis research. Utilizing this technique, specialists will actually want to all the more likely comprehend the multifaceted connections between foundational epigenetic modifications in circling safe cells and changes that happen locally in periodontal inhabitant cells at different periods of infection advancement and movement.

## V. CONCLUSIONS AND FUTURE PROSPECTS

Somewhat recently, solid exploratory proof has amassed uncovering that epigenetic administrative pathway are upset in periodontitis. Changes in DNA methylation profiles of qualities engaged with sickness pathogenesis could be used as illness diagnostics, while proteins that control posttranslational histone alterations, especially acetylation, have arisen as captivating focuses for novel host adjustment therapies. Notwithstanding, before these early discoveries can be incorporated into clinical practise, significant gaps in our understanding of epigenetic regulation in periodontitis must be filled. The long-term stability of epigenetic alterations and how they affect gingival cell responses to inflammatory and pathogenic stimuli are yet unknown. Gingival fibroblasts from periodontitis patients maintain their activated phenotype *in vitro* and are more active in response to *P. gingivalis* infection, according to study [112, 113]. Even if the chemical mechanisms underpinning imprinted activation have yet to be discovered, the hypothesis that it is mediated by epigenetic alterations should be investigated experimentally. The finding of epigenetically-driven "innate immunological memory" in macrophages [114] has reignited discussion on whether bacterial infection can have long-term consequences in host cells [115]. It's unknown if gingival cells exposed to oral infections have this type of memory, or assuming that these progressions make patients more defenseless against changes in their oral microbiota creation.

The fast advancement of genomic, epigenomic, and transcriptome technologies has led to the discovery of causal links between epigenetic regulation abnormalities and particular pathogenic pathways in a variety of diseases [10]. These strategies ought to be coordinated in fundamental and clinical examinations to give a far-reaching guide of epigenetic changes in periodontitis and pinpoint the cell types where these progressions happen. Immune cells that penetrate inflamed gingiva and disrupt epigenetic processes have received little attention *in vitro*. Functional studies of individual epigenetic enzymes in periodontitis genesis and development should be supplemented by a thorough examination of the epigenetic environment. These investigations are needed to completely understand the cellular processes that lead to epigenetic changes in periodontitis patients, as well as the pathophysiological repercussions and environmental factors that influence them. The molecular mechanisms underlie epigenetic medicines' anti-inflammatory and bone-protective actions in periodontitis models, including cellular and animal models, should be the focus of future research. The combination of experimental data from high-throughput epigenomic and functional research may improve hypothesis-driven decisions concerning the usefulness of these drugs in the treatment of periodontal disease, particularly HDACi and BET inhibitors.



## REFERENCES

- [1.] Preshaw PM. Host modulation therapy with anti-inflammatory agents. *Periodontology*. 2000;2018(76):131–49.
- [2.] Hajishengallis G, Lamont RJ. Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. *Mol Oral Microbiol*. 2012;27:409–19
- [3.] Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: dynamic communities and host interactions. *Nat Rev Microbiol*. 2018;16:745–59.
- [4.] Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: framework and proposal of a new classification and case definition. *J Periodontol*. 2018;89(Suppl 1):S159–72.
- [5.] Masumoto R, Kitagaki J, Fujihara C, Matsumoto M, Miyauchi S, Asano Y, et al. Identification of genetic risk factors of aggressive periodontitis using genomewide association studies in association with those of chronic periodontitis. *J Periodontal Res*. 2019;54:199–206.
- [6.] Tough DF, Tak PP, Tarakhovskiy A, Prinjha RK. Epigenetic drug discovery: breaking through the immune barrier. *Nat Rev Drug Discov*. 2016;15:835–53.
- [7.] Zhang Z, Zhang R. Epigenetics in autoimmune diseases: pathogenesis and prospects for therapy. *Autoimmun Rev*. 2015;14:854–63.
- [8.] Larsson L. Current concepts of epigenetics and its role in periodontitis. *Curr Oral Heal Rep*. 2017;4:286–93.
- [9.] Deans C, Maggert KA. What do you mean, “epigenetic”? *Genetics*. 2015;199:887–96.
- [10.] Bird A. Perceptions of epigenetics. *Nature*. 2007;447:396–8.
- [11.] Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. *Genes Dev*. 2009;23:781–3.
- [12.] Rothbart SB, Strahl BD. Interpreting the language of histone and DNA modifications. *Biochim Biophys Acta*. 2014;1839:627–43.
- [13.] Lio CWJ, Rao A. TET enzymes and 5hmC in adaptive and innate immune systems. *Front Immunol*. 2019;10:210.
- [14.] Pfeifer GP, Szabó PE, Song J. Protein interactions at oxidized 5-methylcytosine bases. *J Mol Biol*. 2020;432:1718–30.
- [15.] Zeybel M, Hardy T, Wong YK, Mathers JC, Fox CR, Gackowska A, et al. Multigenerational epigenetic adaptation of the hepatic wound-healing response. *Nat Med*. 2012;18:1369–77.
- [16.] Alabert C, Barth TK, Reverón-Gómez N, Sidoli S, Schmidt A, Jensen ON, et al. Two distinct modes for propagation of histone PTMs across the cell cycle. *Genes Dev*. 2015;29:585–90.
- [17.] Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. *Annu Rev Biochem*. 2007;76:75–100.
- [18.] Marmorstein R, Zhou M-M. Writers and readers of histone acetylation: structure, mechanism, and inhibition. *Cold Spring Harb Perspect Biol*. 2014;6:a018762–a018762.
- [19.] Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. *J Biomed Biotechnol*. 2011;2011:371832.
- [20.] Grabiec AM, Potempa J. Epigenetic regulation in bacterial infections: targeting histone deacetylases. *Crit Rev Microbiol*. 2018;44:336–50.
- [21.] Zhang T, Cooper S, Brockdorf N. The interplay of histone modifications—writers that read. *EMBO Rep*. 2015;16:1467–81.
- [22.] Luan X, Zhou X, Naqvi A, Francis M, Foyle D, Nares S, et al. MicroRNAs and immunity in periodontal health and disease. *Int J Oral Sci*. 2018;10:24.
- [23.] Asa’ad F, Garaicoa-Pazmiño C, Dahlin C, Larsson L. Expression of MicroRNAs in periodontal and peri-implant diseases: a systematic review and meta-analysis. *Int J Mol Sci*. 2020;21:4147.
- [24.] Asa’ad F, Monje A, Larsson L. Role of epigenetics in alveolar bone resorption and regeneration around periodontal and peri-implant tissues. *Eur J Oral Sci*. 2019;127:477–93.
- [25.] Barros SP, Fahimipour F, Tarran R, Kim S, Scarel-Caminaga RM, Justice A, et al. Epigenetic reprogramming in periodontal disease: dynamic crosstalk with potential impact in oncogenesis. *Periodontology*. 2000;2020(82):157–72.
- [26.] Ateia IM, Sutthiboonyanan P, Kamarajan P, Jin T, Godovikova V, Kapila YL, et al. *Treponema denticola* increases MMP-2 expression and activation in the periodontium via reversible DNA and histone modifications. *Cell Microbiol*. 2018;20:1–17.
- [27.] Cantley MD, Dharmapatni AA, Algate K, Crotti TN, Bartold PM, Haynes DR. Class I and II histone deacetylase expression in human chronic periodontitis gingival tissue. *J Periodontal Res*. 2016;51:143–51.
- [28.] Grabiec AM, Reedquist KA. Histone deacetylases in RA: epigenetics and epiphenomena. *Arthritis Res Ther*. 2010;12:142.
- [29.] Grabiec AM, Reedquist KA. The ascent of acetylation in the epigenetics of rheumatoid arthritis. *Nat Rev Rheumatol*. 2013;9:311–8.
- [30.] Angiolilli C, Grabiec AM, Ferguson BS, Ospelt C, Malvar Fernandez B, van Es IE, et al. Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression. *Ann Rheum Dis*. 2016;75:430–8.
- [31.] Martins MD, Jiao Y, Larsson L, Almeida LO, Garaicoa-Pazmino C, Le JM, et al. Epigenetic modifications of histones in periodontal disease. *J Dent Res*. 2016;95:215–22.
- [32.] Seeley JJ, Ghosh S. Molecular mechanisms of innate memory and tolerance to LPS. *J Leukoc Biol*. 2017;101:107–19.
- [33.] Wang P, Yue J, Xu W, Chen X, Yi X, Ye L, et al. Jumonji domain-containing protein 3 regulates the early inflammatory response epigenetically in human periodontal ligament cells. *Arch Oral Biol*. 2018;93:87–94.

- [34.] Francis M, Gopinathan G, Salapatas A, Nares S, Gonzalez M, Diekwisch TGH, et al. SETD1 and NF- $\kappa$ B regulate periodontal inflammation through H3K4 trimethylation. *J Dent Res.* 2020;99:1486–93.
- [35.] Francis M, Pandya M, Gopinathan G, Lyu H, Ma W, Foyle D, et al. Histone methylation mechanisms modulate the inflammatory response of periodontal ligament progenitors. *Stem Cells Dev.* 2019;28:1015
- [36.] Francis M, Gopinathan G, Foyle D, Fallah P, Gonzalez M, Luan X, et al. Histone methylation: achilles heel and powerful mediator of periodontal homeostasis. *J Dent Res.* 2020;99:1332–40.
- [37.] Niederman R, Buyle-Bodin Y, Lu BY, Robinson P, Naleway C. Short-chain carboxylic acid concentration in human gingival crevicular fluid. *J Dent Res.* 1997;76:575–9.
- [38.] Niederman R, Buyle-Bodin Y, Lu BY, Naleway C, Robinson P, Kent R. The relationship of gingival crevicular fluid short chain carboxylic acid concentration to gingival inflammation. *J Clin Periodontol.* 1996;23:743–9.
- [39.] Koike R, Nodomi K, Watanabe N, Ogata Y, Takeichi O, Takei M, et al. Butyric acid in saliva of chronic periodontitis patients induces transcription of the EBV lytic switch activator BZLF1: a pilot study. *Vivo.* 2020;34:587–94.
- [40.] Imai K, Inoue H, Tamura M, Cueno ME, Inoue H, Takeichi O, et al. The periodontal pathogen *Porphyromonas gingivalis* induces the Epstein-Barr virus lytic switch transactivator ZEBRA by histone modification. *Biochimie.* 2012;94:839–46.
- [41.] Yu X, Shahir A-M, Sha J, Feng Z, Eapen B, Nithianantham S, et al. Short-chain fatty acids from periodontal pathogens suppress histone deacetylases, EZH2, and SUV39H1 to promote Kaposi's sarcoma-associated herpesvirus replication. *J Virol.* 2014;88:4466–79.
- [42.] Shirasugi M, Nishioka K, Yamamoto T, Nakaya T, Kanamura N. Normal human gingival fibroblasts undergo cytoapoptosis and apoptosis after long-term exposure to butyric acid. *Biochem Biophys Res Commun.* 2017;482:1122–8.
- [43.] Tsuda H, Ochiai K, Suzuki N, Otsuka K. Butyrate, a bacterial metabolite, induces apoptosis and autophagic cell death in gingival epithelial cells. *J Periodontal Res.* 2010;45:626–34.
- [44.] Chang M-C, Chen Y-J, Lian Y-C, Chang B-E, Huang C-C, Huang W-L, et al. Butyrate stimulates histone H3 acetylation, 8-isoprostane production, RANKL expression, and regulated osteoprotegerin expression/secretion in MG-63 osteoblastic cells. *Int J Mol Sci.* 2018;19:4071.
- [45.] Lucas S, Omata Y, Hofmann J, Böttcher M, Iljazovic A, Sarter K, et al. Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss. *Nat Commun.* 2018;9:55.
- [46.] Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. *Nat Rev Drug Discov.* 2012;11:384–400.
- [47.] Grabiec AM, Tak PP, Reedquist KA. Function of histone deacetylase inhibitors in inflammation. *Crit Rev Immunol.* 2011;31:233–63.
- [48.] Lagosz KB, Bysiek A, Macina JM, Bereta GP, Kantorowicz M, Lipska W, et al. HDAC3 regulates gingival fibroblast inflammatory responses in periodontitis. *J Dent Res.* 2020;99:98–106.
- [49.] Angiolilli C, Kabala PA, Grabiec AM, Van Baarsen IM, Ferguson BS, García S, et al. Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. *Ann Rheum Dis.* 2017;76:277–85.
- [50.] Chen X, Barozzi I, Termanini A, Prosperini E, Recchiuti A, Dalli J, et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. *Proc Natl Acad Sci USA.* 2012;109:E865.
- [51.] Kim T-I, Han J-E, Jung H-M, Oh J-H, Woo KM. Analysis of histone deacetylase inhibitor-induced responses in human periodontal ligament fibroblasts. *Biotechnol Lett.* 2013;35:129–33.
- [52.] Huynh NCN, Everts V, Pavasant P, Ampornaramveth RS. Inhibition of histone deacetylases enhances the osteogenic differentiation of human periodontal ligament cells. *J Cell Biochem.* 2016;117:1384–95.
- [53.] Yedery R, Jerse A. Augmentation of cationic antimicrobial peptide production with histone deacetylase inhibitors as a novel epigenetic therapy for bacterial infections. *Antibiotics.* 2015;4:44–61.
- [54.] Joly S, Maze C, McCray PB, Guthmiller JM. Human  $\beta$ -defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. *J Clin Microbiol.* 2004;42:1024–9.
- [55.] Shang L, Deng D, Buskermolen JK, Janus MM, Krom BP, Rofel S, et al. Multi-species oral biofilm promotes reconstructed human gingiva epithelial barrier function. *Sci Rep.* 2018;8:16061.
- [56.] Prinjha RK, Witherington J, Lee K. Place your BETs: the therapeutic potential of bromodomains. *Trends Pharmacol Sci.* 2012;33:146–53.
- [57.] Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung C-W, et al. Suppression of inflammation by a synthetic histone mimic. *Nature.* 2010;468:1119–23.
- [58.] Klein K, Kabala PA, Grabiec AM, Gay RE, Kolling C, Lin L-L, et al. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. *Ann Rheum Dis.* 2016;75:422–9.
- [59.] Mele DA, Salmeron A, Ghosh S, Huang H-R, Bryant BM, Lora JM. BET bromodomain inhibition suppresses TH17-mediated pathology. *J Exp Med.* 2013;210:2181–90.
- [60.] Maksylewicz A, Bysiek A, Lagosz KB, Macina JM, Kantorowicz M, Bereta G, et al. BET bromodomain inhibitors suppress inflammatory activation of gingival fibroblasts and epithelial cells from periodontitis patients. *Front Immunol.* 2019;10:933.
- [61.] Stadler AF, Angst PDM, Arce RM, Gomes SC, Oppermann RV, Susin C. Gingival crevicular fluid levels of cytokines/chemokines in chronic

- periodontitis: a meta-analysis. *J Clin Periodontol.* 2016;43:727–45.
- [62.] Li Q, Liu F, Dang R, Feng C, Xiao R, Hua Y, et al. Epigenetic modifier trichostatin A enhanced osteogenic differentiation of mesenchymal stem cells by inhibiting NF- $\kappa$ B (p65) DNA binding and promoted periodontal repair in rats. *J Cell Physiol.* 2020;235:9691–701.
- [63.] Cantley MD, Bartold PM, Marino V, Fairlie DP, Le GT, Lucke AJ, et al. Histone deacetylase inhibitors and periodontal bone loss. *J Periodontal Res.* 2011;46:697–703.
- [64.] Meng S, Zhang L, Tang Y, Tu Q, Zheng L, Yu L, et al. BET inhibitor JQ1 blocks inflammation and bone destruction. *J Dent Res.* 2014;93:657–62.
- [65.] Cantley MD, Zannettino ACW, Bartold PM, Fairlie DP, Haynes DR. Histone deacetylases (HDAC) in physiological and pathological bone remodelling. *Bone.* 2017;95:162–74.
- [66.] Jacques C, Lavaud M, Georges S, Tesfaye R, Baud'huin M, Lamoureux F, et al. BET bromodomains' functions in bone-related pathologies. *Epigenomics.* 2020;12:127–44.
- [67.] Roger T, Lugin J, Le Roy D, Goy G, Mombelli M, Koessler T, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. *Blood.* 2011;117:1205–17.
- [68.] Wienerroither S, Rauch I, Rosebrock F, Jamieson AM, Bradner J, Muhar M, et al. Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins. *Mol Cell Biol.* 2014;34:415–27.
- [69.] Zhang S, Crivello A, Ofenbacher S, Moretti A, Paquette DW, Barros SP. Interferon-gamma promoter hypomethylation and increased expression in chronic periodontitis. *J Clin Periodontol.* 2010;37:953–61.
- [70.] Asa'ad F, Bollati V, Pagni G, Castilho RM, Rossi E, Pomingi F, et al. Evaluation of DNA methylation of inflammatory genes following treatment of chronic periodontitis: a pilot case-control study. *J Clin Periodontol.* 2017;44:905–14.
- [71.] Barros SP, Ofenbacher S. Modifiable risk factors in periodontal disease: epigenetic regulation of gene expression in the inflammatory response. *Periodontology.* 2000;2014(64):95–110.
- [72.] De Souza AP, Planello AC, Marques MR, De Carvalho DD, Line SRP. High-throughput DNA analysis shows the importance of methylation in the control of immune inflammatory gene transcription in chronic periodontitis. *Clin Epigenetics.* 2014;6:15.
- [73.] Schulz S, Immel UD, Just L, Schaller H-G, Gläser C, Reichert S. Epigenetic characteristics in inflammatory candidate genes in aggressive periodontitis. *Hum Immunol.* 2016;77:71–5.
- [74.] Kojima A, Kobayashi T, Ito S, Murasawa A, Nakazono K, Yoshie H. Tumor necrosis factor- $\alpha$  gene promoter methylation in Japanese adults with chronic periodontitis and rheumatoid arthritis. *J Periodontal Res.* 2016;51:350–8.
- [75.] Ishida K, Kobayashi T, Ito S, Komatsu Y, Yokoyama T, Okada M, et al. Interleukin-6 gene promoter methylation in rheumatoid arthritis and chronic periodontitis. *J Periodontol.* 2012;83:917–25.
- [76.] Larsson L, Thorbert-Mros S, Lopez-Lago A, Kalm J, Shikhan A, Berglundh T. Expression of TET2 enzyme indicates enhanced epigenetic modification of cells in periodontitis. *Eur J Oral Sci.* 2016;124:329–33.
- [77.] Kurushima Y, Tsai P-C, Castillo-Fernandez J, Couto Alves A, El-Sayed Moustafa JS, Le Roy C, et al. Epigenetic findings in periodontitis in UK twins: a cross-sectional study. *Clin Epigenetics.* 2019;11:27.
- [78.] Andia DC, de Oliveira NFP, Casarin RCV, Casati MZ, Line SRP, de Souza AP. DNA methylation status of the IL8 gene promoter in aggressive periodontitis. *J Periodontol.* 2010;81:1336–41.
- [79.] Baptista NB, Portinho D, Casarin RCV, Vale HF, Casati MZ, De Souza AP, et al. DNA methylation levels of SOCS1 and LINE-1 in oral epithelial cells from aggressive periodontitis patients. *Arch Oral Biol.* 2014;59:670–8.
- [80.] Yang AS, Estécio MRH, Doshi K, Kondo Y, Tajara EH, Issa J-PJ. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. *Nucleic Acids Res.* 2004;32:e38.
- [81.] Wei Y, Shi M, Zhen M, Wang C, Hu W, Nie Y, et al. Comparison of subgingival and buccal mucosa microbiome in chronic and aggressive periodontitis: a pilot study. *Front Cell Infect Microbiol.* 2019;9:53.
- [82.] de Camargo PG, Guimarães GN, Planello AC, Santamaria MP, de Souza AP, Line SR, et al. Porphyromonas gingivalis LPS stimulation downregulates DNMT1, DNMT3a, and JMJD3 gene expression levels in human HaCaT keratinocytes. *Clin Oral Investig.* 2013;17:1279–85.
- [83.] de Faria Amorim SA, Araújo TC, Saraiva AM, Gomez RS, Dutra WO, da Costa JE, et al. Hypermethylation and low transcription of TLR2 gene in chronic periodontitis. *Hum Immunol.* 2013;74:1231–6.
- [84.] Lundmark A, Gerasimcik N, Båge T, Jemt A, Mollbrink A, Salmén F, et al. Gene expression profiling of periodontitis-affected gingival tissue by spatial transcriptomics. *Sci Rep.* 2018;8:9370.
- [85.] Scantamburlo G, Vanoni S, Dossena S, Soyak SM, Bernardinelli E, Civello DA, et al. Interleukin-4 induces CpG site-specific demethylation of the pndrin promoter in primary human bronchial epithelial cells. *Cell Physiol Biochem.* 2017;41:1491–502.
- [86.] Pacis A, Mailhot-Léonard F, Tailleux L, Randolph HE, Yotova V, Dumaine A, et al. Gene activation precedes DNA demethylation in response to infection in human dendritic cells. *Proc Natl Acad Sci U S A.* 2019;116:6938–43.
- [87.] Kurdyukov S, Bullock M. DNA methylation analysis: choosing the right method. *Biology (Basel).* 2016;5:3.
- [88.] Liang L, Cookson WOC. Grasping nettles: cellular heterogeneity and other confounders in epigenome-wide association studies. *Hum Mol Genet.* 2014;23:R83–8.



- [89.] Nociti FH, Casati MZ, Duarte PM. Current perspective of the impact of smoking on the progression and treatment of periodontitis. *Periodontol.* 2000;2015(67):187–210.
- [90.] Fragou D, Pakkidi E, Aschner M, Samanidou V, Kovatsi L. Smoking and DNA methylation: correlation of methylation with smoking behavior and association with diseases and fetus development following prenatal exposure. *Food Chem Toxicol.* 2019;129:312–27.
- [91.] Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY).* 2018;10:573–91.
- [92.] Quach A, Levine ME, Tanaka T, Lu AT, Chen BH, Ferrucci L, et al. Epigenetic clock analysis of diet, exercise, education, and lifestyle factors. *Aging (Albany NY).* 2017;9:419–46.
- [93.] Bartold PM. Lifestyle and periodontitis: the emergence of personalized periodontics. *Periodontology.* 2000;2018(78):7–11.
- [94.] Benakanakere M, Abdolhosseini M, Hosur K, Finoti LS, Kinane DF. TLR2 promoter hypermethylation creates innate immune dysbiosis. *J Dent Res.* 2015;94:183–91.
- [95.] Burns E, Bachrach G, Shapira L, Nussbaum G. Cutting edge: TLR2 is required for the innate response to *Porphyromonas gingivalis*: activation leads to bacterial persistence and TLR2 deficiency attenuates induced alveolar bone resorption. *J Immunol.* 2006;177:8296–300.
- [96.] Barros SP, Hefni E, Fahimipour F, Kim S, Arora P. Maintaining barrier function of infected gingival epithelial cells by inhibition of DNA methylation. *J Periodontol.* 2020;91(Suppl 1):S68-78.
- [97.] Shi D-Q, Ali I, Tang J, Yang W-C. New insights into 5hmC DNA modification: generation. *Distrib Funct Front Genet.* 2017;8:100.
- [98.] Huang Y, Tian C, Li Q, Xu Q. TET1 knockdown inhibits *Porphyromonas gingivalis* LPS/IFN- $\gamma$ -induced M1 macrophage polarization through the NF- $\kappa$ B pathway in THP-1 cells. *Int J Mol Sci.* 2019;20:2023.
- [99.] Wang X, Feng Z, Li Q, Yi B, Xu Q. DNA methylcytosine dioxygenase ten-eleven translocation 2 enhances lipopolysaccharide-induced cytokine expression in human dental pulp cells by regulating MyD88 hydroxymethylation. *Cell Tissue Res.* 2018;373:477–85.
- [100.] Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. *Nature.* 2015;525:389–93.
- [101.] Palioto DB, Finoti LS, Kinane DF, Benakanakere M. Epigenetic and inflammatory events in experimental periodontitis following systemic microbial challenge. *J Clin Periodontol.* 2019;46:819–29.
- [102.] Löe H, Theilade E, Jensen SB. Experimental gingivitis in man. *J Periodontol.* 1965;36:177–87.
- [103.] Dumitrescu RG. Early epigenetic markers for precision medicine. *Methods Mol Biol.* 2018;1856:3–17.
- [104.] Jain S, Wojdacz TK, Su Y-H. Challenges for the application of DNA methylation biomarkers in molecular diagnostic testing for cancer. *Expert Rev Mol Diagn.* 2013;13:283–94.
- [105.] Somineni HK, Venkateswaran S, Kilaru V, Marigorta UM, Mo A, Okou DT, et al. Blood-derived DNA methylation signatures of Crohn's disease and severity of intestinal inflammation. *Gastroenterology.* 2019;156(2254–2265):e3.
- [106.] Zhao M, Zhou Y, Zhu B, Wan M, Jiang T, Tan Q, et al.IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus. *Ann Rheum Dis.* 2016;75:1998–2006.
- [107.] Nair N, Plant D, Verstappen SM, Isaacs JD, Morgan AW, Hyrich KL, et al. Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. *Rheumatology (Oxford).* 2020;59:1364–71.
- [108.] Gao X, Jia M, Zhang Y, Breitling LP, Brenner H. DNA methylation changes of whole blood cells in response to active smoking exposure in adults: a systematic review of DNA methylation studies. *Clin Epigenetics.* 2015;7:113.
- [109.] Choi SW, Braun T, Henig I, Gatza E, Magenau J, Parkin B, et al. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. *Blood.* 2017;130:1760–7.
- [110.] Vojinovic J, Damjanov N, D'Urzo C, Furlan A, Susic G, Pasic S, et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. *Arthritis Rheum.* 2011;63:1452–8
- [111.] Lajosz KB, Grabiec AM. Targeting histone deacetylases for bacterial infections. In: Castelo-Branco P, Jeronimo C, editors. *Histone modifications in therapy.* Cambridge: Academic Press; 2020. p. 237–54.
- [112.] Scheres N, Laine ML, Sipos PM, Bosch-Tijhof CJ, Crielaard W, de Vries TJ, et al. Periodontal ligament and gingival fibroblasts from periodontitis patients are more active in interaction with *Porphyromonas gingivalis*. *J Periodontol Res.* 2011;46:407–16.
- [113.] Baek KJ, Choi Y, Ji S. Gingival fibroblasts from periodontitis patients exhibit inflammatory characteristics in vitro. *Arch Oral Biol.* 2013;58:1282–92.
- [114.] Saeed S, Quintin J, Kerstens HHD, Rao NA, Matarese F, Cheng S, et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. *Science.* 2014;345:1251086.
- [115.] Pereira JM, Hamon MA, Cossart P. A lasting impression: epigenetic memory of bacterial infections? *Cell Host Microbe.* 2016;19:579–82